pharmaceutical investing Opiant Pharmaceuticals Announces Contract with Biomedical Advanced Research and Development Authority for Up to $4.6 Million to Accelerate Development of OPNT003
pharmaceutical investing Opiant Pharmaceuticals Announces Final Patient Enrolled in Phase 2 Clinical Trial Evaluating OPTN001 in Bulimia Nervosa
EnerCom Announces Initial List of Presenting Companies for the 31st Annual Energy Investment Conference to be held August 17-19, 2026, in Denver, Colorado
